The insulin receptor (IR) is a prototypical receptor tyrosine kinase that orchestrates critical cellular processes, including metabolism, cell growth and differentiation. Activation of the IR involves ...
In the meta-analysis, the median follow-up ranged from 2 to 14 years and the median OS was between 10.1 and 12.7 months (where reported). Comparing patients with tumors NTRK+ and NTRK–, the pooled HR ...
Glenmark Pharmaceuticals has partnered with China's Hansoh Pharma to commercialize Aumolertinib, a drug for non-small cell lung cancer, across multiple global markets. The agreement grants Glenmark ...
MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR: Dose-escalation phase I study. This is an ASCO Meeting Abstract from the 2012 ASCO Annual Meeting I. This abstract ...
Glenmark enters collaboration and distribution agreement with Jiangsu Hansoh Pharma for Aumolertinib, a third-generation GFR-TKI to treat NSCLC: Our Bureau, Mumbai Wednesday, Dece ...
Bruton’s tyrosine kinase inhibitors such as ibrutinib have significantly improved outcomes for chronic lymphocytic leukemia, but they can cause long-term toxicities, and patients must remain on them ...
TipRanks on MSN
Pfizer announces results from HER2CLIMB-05 trial
Pfizer (PFE) announced results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor Tukysa as part of an investigational ...
Inebilizumab-cdon is approved for anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody–positive generalized myasthenia gravis, based on MINT trial results. Inebilizumab gains ...
US biotech Amgen (Nasdaq: AMGN) has won approval from the US regulator for Uplizna (inebilizumab-cdon) to treat adults with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback